Contracts Finder

NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National

NHS England

Awarded
goods
SME-friendly
Framework agreement

Published on NHS Health Family Atamis procurement portal

This tender has closed

The submission deadline for this contract has passed. There may be more active goods tenders from NHS England, and hundreds more across the UK public sector.

Key details

Contracting authority
NHS England
nhs
Region
Runcorn
Sector
Healthcare & Medical
Contract value
£261,895,933ex VAT
Submissions closed
18 March 2025
Published
10 February 2025

Procurement

Contract period
1 September 2025 - 31 August 2027
2 years
Procedure type
Open procedure (above threshold)
CPV classifications
  • 33600000 Pharmaceutical products

What happened

NHS England awarded this contract to Roche Products Ltd | Amgen Ltd | Seqirus UK Limited | Biogen | Teva UK Limited | Dr.Reddy's Laboratories (UK) Limited | Orifarm UK | Pfizer Ltd | Vifor Pharma UK Ltd | Accord-UK Ltd | Sandoz Ltd | Eli Lilly & Company Ltd | Chugai Pharma UK Ltd | Mylan | Aventis Pharma ltd t/a Sanofi | Manx Healthcare Ltd | Janssen-Cilag Ltd | Novo Nordisk | Sun Pharma UK Ltd | Merck Serono Limited | Bayer Plc | Napp Pharmaceuticals Ltd | AstraZeneca | CST Pharma Limited | Pharmacosmos UK Ltd | Thornton and Ross Ltd | GlaxoSmithKline UK Limited | Gedeon Richter UK Ltd worth £261,895,933 on 25 Jun 2025. The contract runs until 31 Aug 2027.

Description

NHS Framework Agreement for Branded Medicines - Tranche A London and South of England and Adult Influenza (National) - 01 September 2025 Offer reference number: CM/PHR/24/5718

CM/PHR/24/5718/01 - NHS Framework Agreement for Branded Medicines - Tranche A for London and South of England. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5718/02 - NHS Framework Agreement for Branded Medicines - Adult Influenza (National). Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months.

Awarded suppliers (28)

Suppliers
  • Roche Products Ltd
  • Amgen Ltd
  • Seqirus UK Limited
  • Biogen
  • Teva UK Limited
  • Dr.Reddy's Laboratories (UK) Limited
  • Orifarm UK
  • Pfizer Ltd
  • Vifor Pharma UK Ltd
  • Accord-UK Ltd
  • Sandoz Ltd
  • Eli Lilly & Company Ltd
  • Chugai Pharma UK Ltd
  • Mylan
  • Aventis Pharma ltd t/a Sanofi
  • Manx Healthcare Ltd
  • Janssen-Cilag Ltd
  • Novo Nordisk
  • Sun Pharma UK Ltd
  • Merck Serono Limited
  • Bayer Plc
  • Napp Pharmaceuticals Ltd
  • AstraZeneca
  • CST Pharma Limited
  • Pharmacosmos UK Ltd
  • Thornton and Ross Ltd
  • GlaxoSmithKline UK Limited
  • Gedeon Richter UK Ltd
Award value
£261,895,933
Award date
25 June 2025

Contact

Address
2nd Floor, Rutland House, Runcorn, WA7 2ES
Contact name
Lynne Tierney
Email
[email protected]

Identifiers

Buyer reference
CF-3097600D0O000000rwimUAA
Notice ID
8a3e4a3c-0b35-41dd-a894-6b259747485a-855876
OCID
ocds-b5fd17-5ea01c9a-8442-488c-bb4a-cdfa18d54a6c

Explore related tenders

Other tenders from NHS England

View all →
Secondary Care Medicines Data Pre-Market Engagement£6,750,000
Quality Assurance & Improvement of Structured Learning Placement (SLP) Modules£98,000
Targeted Prostate Cancer Screening Programme - MRI Reporting Service
Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service
Strengthening Cultural Capability and Trauma Informed Care in Women’s Health£175,000

External ID: cf-ocds-b5fd17-5ea01c9a-8442-488c-bb4a-cdfa18d54a6c • Added 3 October 2026